Spironolactone-Induced Acid-Base Disturbances

Introduction to Spironolactone Mechanism

• Spironolactone acts as an aldosterone antagonist, increasing natriuresis and conserving potassium in the distal tubules, which can lead to metabolic acidosis, specifically a hyperchloremic normal anion gap metabolic acidosis, due to its inhibition of aldosterone action in the distal tubule 1

Monitoring and Management Guidelines

• The European Society of Cardiology recommends regular monitoring of serum electrolytes when using spironolactone, with guidelines suggesting checks at 1 and 4 weeks after starting treatment and after dose increases 2, 3
• Patients with pre-existing renal impairment or liver disease, such as cirrhosis, are at higher risk of spironolactone-induced metabolic acidosis and require closer monitoring 3

Interaction with Other Medications

• When spironolactone is used with loop diuretics like furosemide, the metabolic alkalosis typically caused by loop diuretics may partially offset spironolactone's acidosis-inducing effects 1

Clinical Implications and Recommendations

• Clinicians should be vigilant about potential acid-base disturbances, particularly hyperchloremic metabolic acidosis, and consider dose reduction or discontinuation of spironolactone if significant acidosis develops 2, 3